184 related articles for article (PubMed ID: 12162451)
1. Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.
Samuni AM; DeGraff W; Krishna MC; Mitchell JB
Mol Cell Biochem; 2002; 234-235(1-2):327-33. PubMed ID: 12162451
[TBL] [Abstract][Full Text] [Related]
2. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
Plumb JA; Gerritsen M; Workman P
Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of hypoxic and aerobic cytotoxicity of mitomycin C in Chinese hamster V79 cells.
Krishna MC; DeGraff W; Tamura S; Gonzalez FJ; Samuni A; Russo A; Mitchell JB
Cancer Res; 1991 Dec; 51(24):6622-8. PubMed ID: 1660344
[TBL] [Abstract][Full Text] [Related]
4. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
5. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
Bailey SM; Lewis AD; Patterson LH; Fisher GR; Knox RJ; Workman P
Biochem Pharmacol; 2001 Aug; 62(4):461-8. PubMed ID: 11448456
[TBL] [Abstract][Full Text] [Related]
6. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites.
Bailey SM; Lewis AD; Knox RJ; Patterson LH; Fisher GR; Workman P
Biochem Pharmacol; 1998 Sep; 56(5):613-21. PubMed ID: 9783730
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing nitroxide reduction and cytotoxicity in vitro.
Samuni Y; Gamson J; Samuni A; Yamada K; Russo A; Krishna MC; Mitchell JB
Antioxid Redox Signal; 2004 Jun; 6(3):587-95. PubMed ID: 15130285
[TBL] [Abstract][Full Text] [Related]
8. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
Walton MI; Smith PJ; Workman P
Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284
[TBL] [Abstract][Full Text] [Related]
9. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
10. The autoxidation of the reduced forms of EO9.
Butler J; Spanswick VJ; Cummings J
Free Radic Res; 1996 Aug; 25(2):141-8. PubMed ID: 8885332
[TBL] [Abstract][Full Text] [Related]
11. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P
Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948
[TBL] [Abstract][Full Text] [Related]
12. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
[TBL] [Abstract][Full Text] [Related]
13. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
14. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Jaffar M; Naylor MA; Robertson N; Lockyer SD; Phillips RM; Everett SA; Adams GE; Stratford IJ
Anticancer Drug Des; 1998 Mar; 13(2):105-23. PubMed ID: 9524554
[TBL] [Abstract][Full Text] [Related]
15. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
[TBL] [Abstract][Full Text] [Related]
16. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
17. Modulation of streptonigrin cytotoxicity by nitroxide SOD mimics.
Krishna MC; Halevy RF; Zhang R; Gutierrez PL; Samuni A
Free Radic Biol Med; 1994 Nov; 17(5):379-88. PubMed ID: 7835744
[TBL] [Abstract][Full Text] [Related]
18. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
Collard J; Matthew AM; Double JA; Bibby MC
Br J Cancer; 1995 Jun; 71(6):1199-203. PubMed ID: 7779711
[TBL] [Abstract][Full Text] [Related]
19. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia.
Everett SA; Naylor MA; Nolan J; Patel KB; Wardman P
Anticancer Drug Des; 1998 Sep; 13(6):635-53. PubMed ID: 9755722
[TBL] [Abstract][Full Text] [Related]
20. Free radical modes of cytotoxicity of adriamycin and streptonigrin.
DeGraff W; Hahn SM; Mitchell JB; Krishna MC
Biochem Pharmacol; 1994 Oct; 48(7):1427-35. PubMed ID: 7945443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]